ococcal infections according to current medical guidelines. Counsel patients aboutgonorrhea prevention and advise regular testing for patients at risk. Advise patients toreport any new signs and symptoms of infection.
Discontinuation
Inform patients with PNH that they may develop hemolysis due to PNH whenULTOMIRIS is discontinued and that they will be monitored by their healthcareprofessional for at least 16 weeks following ULTOMIRIS discontinuation.
Inform patients who discontinue ULTOMIRIS to keep the ULTOMIRIS Patient SafetyCard with them for eight months after the last ULTOMIRIS dose, because the increased
risk of meningococcal infection persists for several weeks following discontinuation ofULTOMIRIS.
Infusion reactions
Advise patients that administration of ULTOMIRIS may result in infusion reactions.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761108s000lbl.pdf
|
